

BEXIMCO PHARMACEUTICALS LIMITED

17, DHANMONDI, ROAD NO. 2,
DHAKA-1205

PRICE SENSITIVE INFORMATION

This is for information of all concerned that the Board of Directors of the Company in their meeting held on 28 October, 2020 at 3.30 p.m. has approved the audited Financial Statements for the year ended on 30 June, 2020 and took the following decisions:

1. Recommended Dividend : 15% Cash & 10% Stock Dividend.
2. Record date : 25 November, 2020.
3. Date & Time of 44th AGM : 19 December, 2020 at 10.30 A.M.
4. Venue of 44th AGM : Digital Platform.

Comparative Financial Disclosures:

Beximco Pharmaceuticals Limited (Stand-alone)

Particulars	Year ended 30 June, 2020	Year ended 30 June, 2019
Net Profit after Tax	Tk.3,363,399,873	Tk.3,023,500,974
Earnings Per Share (EPS)	Tk.8.29	Tk.7.46
Net Asset Value (NAV)	Tk.32,356,359,135	Tk.29,600,843,240
Net Asset Value per share (NAVPS)	Tk.79.78	Tk.72.99
Net Operating Cash Flow Per Share (NOCFPS)	Tk.12.85	Tk.6.72

Beximco Pharmaceuticals Limited and its Subsidiaries (Consolidated)

Particulars	Year ended 30 June, 2020	Year ended 30 June, 2019
Net Profit after Tax	Tk. 3,544,483,101	Tk.3,040,402,954
Earnings Per Share (EPS)	Tk.8.67	Tk.7.48
Net Asset Value (NAV)	Tk.32,495,120,607	Tk.29,588,317,284
Net Asset Value per share (NAVPS)	Tk.80.12	Tk.72.96
Net Operating Cash Flow Per Share (NOCFPS)	Tk.13.67	Tk.7.30

By order of the Board,

Sd/-

(MOHAMMAD ASAD ULLAH, FCS)

EXECUTIVE DIRECTOR & COMPANY SECRETARY

Dated: 28 October, 2020